Department of Cellular Biology, Physiology and Immunology, Autonomous University of Barcelona, Bellaterra, Spain.
J Neuroimmunol. 2010 Jun;223(1-2):39-54. doi: 10.1016/j.jneuroim.2010.03.021. Epub 2010 May 6.
Antigen presentation, a key mechanism in immune responses, involves two main signals: the first is provided by the engagement of a major histocompatibility complex (MHC), class I or class II, with their TCR receptor in lymphocytes, whereas the second demands the participation of different co-stimulatory molecules, such as CD28, CTLA-4 and their receptors B7.1 and B7.2. Specific T-cell activation and deactivation are achieved through this signalling. The aim of our study is to characterise, in the acute experimental autoimmune encephalomyelitis (EAE) model in Lewis rat, the temporal expression pattern of these molecules as well as the cells responsible for their expression. To accomplish that, MBP-immunised female Lewis rats were daily examined for the presence of clinical symptoms and sacrificed, according to their clinical score, at different phases during EAE. Spinal cords were cut with a cryostat and processed for immunohistochemistry: MHC-class I and MHC-class II, co-stimulatory molecules (B7.1, B7.2, CD28, CTLA-4) and markers of dendritic cells (CD1 for immature cells and fascin for mature cells). Our results show that microglial cells are activated in the inductive phase and, during this phase and peak, they are able to express MHC-class I, MHC-class II and CD1, but not B7.1 and B7.2. This microglial phenotype may induce the apoptosis or anergy of infiltrated CD28+ lymphocytes observed around blood vessels and in the parenchyma. During the recovery phase, microglial cells express high MHC-class I and class II and, those located in the surroundings of blood vessels, displayed the B7.2 co-stimulatory molecule. These cells are competent to interact with CTLA-4+ cells, which indicate an active role of microglial cells in modulating the ending of the immune response by inducing lymphocyte activity inhibition and Treg activation. Once clinical symptomatology disappeared, some foci of activated microglial cells (MHC-class II+/B7.2+) were still present in concomitance with CTLA-4+ cells, suggesting a prolonged involvement of microglia in lymphocyte inhibition and tolerance promotion. In addition to microglia, during the inductive and recovery phases, we also found perivascular ED2+ cells and fascin+ cells which are able to migrate to the parenchyma and may play a role in lymphocytic regulation. Further studies to understand the specific function played by these cells are warranted.
抗原呈递是免疫反应的一个关键机制,涉及两个主要信号:第一个信号是主要组织相容性复合体 (MHC) Ⅰ类或Ⅱ类与淋巴细胞上的 TCR 受体的结合提供的,而第二个信号则需要不同共刺激分子的参与,如 CD28、CTLA-4 及其受体 B7.1 和 B7.2。通过这种信号转导实现特定 T 细胞的激活和失活。我们的研究目的是在 Lewis 大鼠的急性实验性自身免疫性脑脊髓炎 (EAE) 模型中,描述这些分子的时间表达模式以及负责其表达的细胞。为此,每天检查 MBP 免疫雌性 Lewis 大鼠是否存在临床症状,并根据其临床评分在 EAE 的不同阶段处死。用冷冻切片机切割脊髓并进行免疫组织化学处理:MHC-Ⅰ类和 MHC-Ⅱ类、共刺激分子 (B7.1、B7.2、CD28、CTLA-4) 和树突状细胞标记物 (不成熟细胞的 CD1 和成熟细胞的 fascin)。我们的结果表明,小胶质细胞在诱导期被激活,在此期间和高峰期,它们能够表达 MHC-Ⅰ类、MHC-Ⅱ类和 CD1,但不能表达 B7.1 和 B7.2。这种小胶质细胞表型可能会诱导浸润的 CD28+淋巴细胞凋亡或无能,这些细胞观察到在血管周围和实质中。在恢复期,小胶质细胞表达高水平的 MHC-Ⅰ类和Ⅱ类,并且那些位于血管周围的细胞表达 B7.2 共刺激分子。这些细胞能够与 CTLA-4+细胞相互作用,表明小胶质细胞通过诱导淋巴细胞活性抑制和 Treg 激活来调节免疫反应的结束,从而发挥积极作用。一旦临床症状消失,一些活化的小胶质细胞 (MHC-Ⅱ类+/B7.2+) 焦点仍然与 CTLA-4+细胞共存,这表明小胶质细胞在淋巴细胞抑制和促进耐受方面的参与时间延长。除了小胶质细胞,在诱导期和恢复期,我们还发现了血管周围的 ED2+细胞和 fascin+细胞,它们能够迁移到实质中,并可能在淋巴细胞调节中发挥作用。进一步的研究对于理解这些细胞所发挥的特定功能是必要的。